159 related articles for article (PubMed ID: 23739246)
1. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
2. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
3. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Groesser L; Herschberger E; Landthaler M; Hafner C
Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
5. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX
Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999
[TBL] [Abstract][Full Text] [Related]
6. Somatic FGFR3 and PIK3CA mutations are present in familial seborrhoeic keratoses.
Hafner C; Vogt T; Landthaler M; Müsebeck J
Br J Dermatol; 2008 Jul; 159(1):214-7. PubMed ID: 18503601
[TBL] [Abstract][Full Text] [Related]
7. [Genetic basis of seborrheic keratosis and epidermal nevi].
Hafner C; Hafner H; Groesser L
Pathologe; 2014 Sep; 35(5):413-23. PubMed ID: 25187080
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.
Hafner C; Landthaler M; Mentzel T; Vogt T
Br J Dermatol; 2010 Mar; 162(3):508-12. PubMed ID: 19845664
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Landthaler M; Hartmann A; Vogt T
Br J Dermatol; 2009 Mar; 160(3):546-51. PubMed ID: 19076977
[TBL] [Abstract][Full Text] [Related]
10. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
13. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
15. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
[TBL] [Abstract][Full Text] [Related]
16. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses.
Hafner C; Hartmann A; Real FX; Hofstaedter F; Landthaler M; Vogt T
J Invest Dermatol; 2007 Aug; 127(8):1883-5. PubMed ID: 17392824
[TBL] [Abstract][Full Text] [Related]
18. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
19. Frequent activating HRAS mutations in trichilemmoma.
Tsai JH; Huang WC; Jhuang JY; Jeng YM; Cheng ML; Chiu HY; Kuo KT; Liau JY
Br J Dermatol; 2014 Nov; 171(5):1073-7. PubMed ID: 24890286
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Hafner C; López-Knowles E; Luis NM; Toll A; Baselga E; Fernández-Casado A; Hernández S; Ribé A; Mentzel T; Stoehr R; Hofstaedter F; Landthaler M; Vogt T; Pujol RM; Hartmann A; Real FX
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13450-4. PubMed ID: 17673550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
